Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some
Long-term benefits were improved in some patients with advanced non-small cell lung cancer (NSCLC) enrolled in experimental combination groups, although ...
Tag: imfinzi
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
New research shows Imfinzi significantly extends survival for patients with early-stage small cell lung cancer.Patients with limited-stage (cancer that is ...
Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer
Patients with cisplatin-eligible muscle-invasive bladder cancer (MIBC) who received neoadjuvant (treatment as the first step to shrink a tumor) Imfinzi ...
Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC
Imfinzi was not shown to improve disease-free survival in patients with PD-L1-positive NSCLC.Disease-free survival (DFS; time after diagnosis during which ...
A New Era in Small Cell Lung Cancer Treatment
Dr. Debu Tripathy, editor-in-chief of CURE magazineAlthough advancements in treatments for small cell lung cancer (SCLC) are scarce for this ...
Treatment Breakthroughs Arrive for SCLC
Photography by Jill StifflerFor Sabrina Potts, the approval by the Food and Drug Administration (FDA) of Imdelltra (tarlatamab-dlle) in May ...
FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC
The effectiveness of the Imfinzi regimen was evaluated in the phase 3 AEGEAN trial. The Food and Drug Administration (FDA) ...
Top 4 Lung Cancer News Stories of Summer 2024
Here are 4 top lung cancer stories from summer 2024. Ever since the American Society of Clinical Oncology (ASCO) Annual ...
FDA Approvals for Solid Cancers in June
Here are six Food and Drug Administration approvals for solid tumors in June 2024. The Food and Drug Administration (FDA) ...